Reduction of Infusion Time Using a 10% Intravenous Immunoglobulin Formulation With a 15-Minute Rate Escalation Protocol During Staffing Shortages Due to COVID-19.

This was a nonrandomized, retrospective analysis of 23 patients, so the before-after comparison could reflect selection, care changes, or chance rather than the product and protocol alone. Patients were selected for transition based on comorbidities, previous Ig-related adverse reactions, and cost or availability, which may make them different from patients who stayed on other products. The study cannot separate the contribution of the 10% formulation from the 15-minute escalation interval or individual tolerability decisions. Infusion time excluded initial assessment and general documentation but included interruptions, so it is not the full nursing visit time. One patient's pre-transition infusion time was extrapolated after an unrelated weight loss and dose change, which may distort the before-after comparison. The paper does not report statistical tests for the main time change, and the mean change was small with wide variability. Cost estimates used only nursing infusion time at $90 per hour and did not include medication, pharmacy, hospital, or patient time. Documentation of infusion procedures was limited, so some longer infusions may not have been drug related.

Bio Products Laboratory Ltd funded medical writing and editorial support. Medical writing support was provided by Medical Leverage and Edward K. Baldwin, PhD. All authors participated in writing, review, revision, and approval.

Do not read this as proof that the 10% IVIg product with a 15-minute escalation protocol will reliably save infusion time or nursing cost. The mean reduction was 0.2 hours per infusion, 5 patients had no change and 5 had longer infusions, and the study was nonrandomized with manufacturer-funded writing.